US Food and Drug Administration Clinical Investigator Inspections

被引:3
|
作者
Buchmeier, Andrea D. [1 ]
机构
[1] Sarah Cannon Canc Inst, 4900 S Monaco St, Denver, CO 80237 USA
关键词
Food and Drug Administration (FDA); FDA Inspector; FDA Form 483; FDA Form 482; Bioresearch Monitoring Program (BIMO); clinical investigator; research team;
D O I
10.1016/j.soncn.2020.151000
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To review the US Food and Drug Administration (FDA) Bioresearch Monitoring clinical investigator inspection process from start to final classification to support clinical research nurses in practice. Data Sources: Published articles, websites, and author's expertise with FDA inspections. Conclusion: Clinical research nurses should conduct and manage every clinical trial as if it were to be inspected by the FDA. This recommendation is considered best practice for clinical research nurses to prevent last-minute preparations to organize and clean up research data and records retrospectively. Implications for Nursing Practice: This article will assist the oncology research nurse and interdisciplinary research members at the research site in the preparedness for an FDA inspection. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页数:3
相关论文
共 50 条
  • [21] Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
    Fei Liang
    Sheng Zhang
    Qin Wang
    Wenfeng Li
    BMC Cancer, 20
  • [22] Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration
    Tibau, Ariadna
    Molto, Consolacion
    Ocana, Alberto
    Templeton, Arnoud J.
    Del Carpio, Luis P.
    Del Paggio, Joseph C.
    Barnadas, Agusti
    Booth, Christopher M.
    Amir, Eitan
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (05): : 486 - 492
  • [23] The US Food and Drug Administration's Efforts to Support Ophthalmology Clinical Trials
    Eydelman, Malvina B.
    JAMA OPHTHALMOLOGY, 2014, 132 (12) : 1391 - 1392
  • [24] Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
    Liang, Fei
    Zhang, Sheng
    Wang, Qin
    Li, Wenfeng
    BMC CANCER, 2020, 20 (01)
  • [25] Clinical Evaluation of Pertussis Vaccines: US Food and Drug Administration Regulatory Considerations
    Farizo, Karen M.
    Burns, Drusilla L.
    Finn, Theresa M.
    Gruber, Marion F.
    Pratt, R. Douglas
    JOURNAL OF INFECTIOUS DISEASES, 2014, 209 : S28 - S31
  • [27] Surgical Innovation and the US Food and Drug Administration
    Cundiff, Geoffrey W.
    FEMALE PELVIC MEDICINE AND RECONSTRUCTIVE SURGERY, 2019, 25 (04): : 263 - 264
  • [28] US Food and Drug Administration pushed to change
    McCarthy, M
    LANCET, 2006, 367 (9523): : 1643 - 1644
  • [29] Increasing Transparency at the US Food and Drug Administration
    Steinbrook, Robert
    JAMA INTERNAL MEDICINE, 2019, 179 (08) : 1146 - 1147
  • [30] The US Food and Drug Administration and Emergency Contraception
    Fox, Anthony W.
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL MEDICINE, 2005, 19 (03): : 139 - 140